SC
LMAT icon

Scholtz & Company’s LeMaitre Vascular LMAT Stock Holding History

Scholtz & Company’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,200
Closed -$85K – 54
2015
Q1 		$85K Buy
+10,200
New +$80K 0.08% 53

Other funds holding LMAT

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Scholtz & Company's LMAT Position: Q2 2015 in Review

Scholtz & Company sold out of LeMaitre Vascular (LMAT) in Q2 2015, closing a stake of 10,200 shares — an estimated $85K sold.

Scholtz & Company first reported a position in LMAT in Q1 2015 and held it in 1 quarter. The position peaked at $85K in Q1 2015. 75 funds tracked by Wall St. Rank hold LMAT as of Q2 2015.

  • Scholtz & Company reported no remaining LeMaitre Vascular position as of Q2 2015 after selling out during the quarter.
  • Scholtz & Company sold 10,200 LeMaitre Vascular shares in Q2 2015, an estimated $85K.
  • Scholtz & Company first reported a position in LeMaitre Vascular in Q1 2015 and held it in 1 quarter.
  • Scholtz & Company's LeMaitre Vascular position peaked at $85K in Q1 2015.
  • 75 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2015.

Based on Scholtz & Company's 13F filing for Q2 2015, filed 14 Aug 2015.